Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial

Autor: Patrick Gavin Kehoe, Nicholas Turner, Beth Howden, Lina Jarutyte, Shona Louise Clegg, Ian Brian Malone, Josephine Barnes, Casper Nielsen, Carole Hélène Sudre, Aileen Wilson, Ngoc Jade Thai, Peter Sinclair Blair, Elizabeth Coulthard, Janet Athene Lane, Peter Passmore, Jodi Taylor, Henk-Jan Mutsaerts, David Lee Thomas, Nick Charles Fox, Ian Wilkinson, Yoav Ben-Shlomo, Kirsty Harkness, Tarun Kuruvilla, Rupert McShane, Peter Connelly, Gordon Duncan, Lucy Calvert, Alasdair Lawrie, Matthew Sheridan, Eric Jackson, Bernard Udeze, Stephen Pearson, Tobias Langheinrich, Suvarna Wagle, Joseph Butchart, Ajay Macharouthu, Andrew Donaldson, Wendy Neil, Vivek Pattan, David Findlay, Alan Thomas, Robert Barber, Andrew Byrne, Madhusudan Dalvi, Rashi Negi, Bernadette McGuinness

Publikováno v: The Lancet. Neurology
Lancet Neurology, 20(11), 895-906. Lancet Publishing Group
Kehoe, P G, Turner, N, Howden, B, Jarutyte, L, Clegg, S L, Malone, I B, Barnes, J, Nielsen, C, Sudre, C H, Wilson, A, Thai, N J, Blair, P S, Coulthard, E, Lane, J A, Passmore, P, Taylor, J, Mutsaerts, H-J, Thomas, D L, Fox, N C, Wilkinson, I, Ben-Shlomo, Y & RADAR investigators 2021, ' Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial) : a double-blind, randomised, placebo-controlled, phase 2 trial ', Lancet Neurology, vol. 20, no. 11, pp. 895-906 . https://doi.org/10.1016/S1474-4422(21)00263-5
RADAR investigators 2021, ' Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial ', The Lancet. Neurology, vol. 20, no. 11, pp. 895-906 . https://doi.org/10.1016/S1474-4422(21)00263-5
2021, ' Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial) : a double-blind, randomised, placebo-controlled, phase 2 trial ', Lancet Neurology, vol. 20, no. 11, pp. 895-906 . https://doi.org/10.1016/S1474-4422(21)00263-5
Kehoe, P G, Turner, N, Howden, B, Jarutyte, L, Clegg, S L, Malone, I B, Barnes, J, Nielsen, C, Sudre, C H, Wilson, A, Thai, N J, Blair, P S, Coulthard, E, Lane, J A, Passmore, P, Taylor, J, Mutsaerts, H-J, Thomas, D L, Fox, N C, Wilkinson, I & Ben-Shlomo, Y 2021, ' Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial ', Lancet Neurology, vol. 20, no. 11, pp. 895-906 .

BACKGROUND: Drugs modifying angiotensin II signalling could reduce Alzheimer's disease pathology, thus decreasing the rate of disease progression. We investigated whether the angiotensin II receptor antagonist losartan, compared with placebo, could r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4a28429bb9f725cd7e59ecafb894961
http://europepmc.org/articles/PMC8528717

Indicators of dementia disease progression in primary care : an electronic health record cohort study

Autor: Nwe Thein, Peter Croft, Paul Campbell, Carolyn Chew-Graham, Athula Sumathipala, Kelvin P. Jordan, Kate Walters, Louise Robinson, James Bailey, Trishna Rathod-Mistry, Martin Frisher, Scott Weich, Rashi Negi, Swaran P. Singh, Michelle Marshall, Richard Hayward

Background and purpose: The objectives were to assess the feasibility and validity of using markers of dementia‐related health as indicators of dementia progression in primary care, by assessing the frequency with which they are recorded and by tes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9777bb7d2b3b51a9d95ea46f5ac1adf
http://wrap.warwick.ac.uk/151188/1/WRAP-Indicators-dementia-disease-progression-primary-care-electronic-health-record-2021.pdf

Are we adequately reviewing confusion inducing drugs in patients referred to the memory assessment service?

Autor: Rashi Negi, Hari Shanmugaratnam, Siddhant Hegde

Publikováno v: BJPsych Open

AimsThe aim of this quality improvement evaluation project is to establish the standard of current practice in relation to reviewing confusion inducing drugs (CIDs) at the time of referral, as it has been hypothesised that these medications contribut

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29291a8b1d2fc942f313dfeab66f01e8
https://doi.org/10.1192/bjo.2021.520

Psychiatric out-patient clinics for older adults: highly regarded by users and carers, but irreplaceable?

Autor: Nicola Thomas, Christopher Flemons, Jeremy Seymour, Rashi Negi, Rachael Witrylak, Matthew Impey

Publikováno v: Psychiatric Bulletin. 33:127-129

Aims and MethodThe aim of this study was to explore older users' and carers' views of attending out-patient clinics for older adults. A questionnaire was designed to be distributed to all patients attending out-patient clinics for a period of 1 month

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e82314f5ff862bf34b2344cf89d6f7dd
https://doi.org/10.1192/pb.bp.107.016972